Physician

Mark Edward Dowell, M.D.

According to 2025 Medicare claims, Mark Dowell, M.D. (NPI: 1922186733) practices infectious disease in the Casper, WY market, with the plurality of this provider's patient population coming from Natrona, WY. This provider's primary affiliated billing organization is ROCKY MOUNTAIN INFECTIOUS DISEASES (NPI: 1497833180; TIN: 830326365) and primary practice location at 82601-2239. Dowell is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Dowell's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 625 traditional Medicare patients, billed 120,922 HCPCS/CPT codes, and received $248,530 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,019 prescription claims across 146 beneficiaries totaling $831,742 in drug costs, led by Genvoya (Elviteg/Cob/Emtri/Tenof Alafen). DME data shows 19 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $593,689 to $248,530. Similarly, Part D prescription costs have declined steadily, from $1,465,485 to $831,742. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $16,210 to $6,562.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	689	319,405	$593,689
2016	674	99,569	$498,945
2017	670	92,087	$462,298
2018	811	168,137	$511,623
2019	612	117,271	$303,931
2020	543	84,281	$176,823
2021	578	79,335	$199,946
2022	637	134,215	$266,833
2023	596	134,260	$237,571
2024	625	120,922	$248,530

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	125	974	$1,465,485
2016	143	1,080	$1,291,924
2017	145	1,290	$1,293,364
2018	177	1,187	$971,944
2019	119	1,288	$685,061
2020	90	846	$863,383
2021	103	915	$808,104
2022	109	1,174	$1,010,940
2023	142	1,124	$947,328
2024	146	1,019	$831,742

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	193	722	$10,713
2016	195	1,865	$20,774
2017	317	1,511	$14,653
2018	113	470	$5,622
2019	N/R	141	$1,649
2020	N/R	11	$2,269
2021	N/R	23	$2,468
2022	16	71	$6,485
2023	N/R	59	$6,830
2024	N/R	19	$1,656

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	158	233	$134
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	246	319	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	132	165	$67
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	114	401	$48
36415	Insertion of needle into vein for collection of blood sample	154	240	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Genvoya	Elviteg/Cob/Emtri/Tenof Alafen	90	2,700	$371,337
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	34	1,020	$133,419
Descovy	Emtricitabine/Tenofov Alafenam	11	330	$24,355
Isentress	Raltegravir Potassium	12	343	$23,160
Darunavir	Darunavir	11	330	$8,755

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	19	$1,656

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Mark Edward Dowell, M.D.?

Tedicare shows public-source Medicare data for Mark Edward Dowell, M.D. (NPI 1922186733), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Edward Dowell, M.D. have ACO affiliation data?

Mark Edward Dowell, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Mark Edward Dowell, M.D.?

Mark Edward Dowell, M.D. is linked to ROCKY MOUNTAIN INFECTIOUS DISEASES (billing NPI 1497833180) in the available physician profile data.

Does Mark Edward Dowell, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.